Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16)

Oncology Research

Volumn 12, Issue 3, 2000, Pages 113-119

  Rappa, Germana ^a,b   Shyam, Krishnamurthy ^b   Lorico, Aurelio ^a,b   Fodstad, Øystein ^a   Sartorelli, Alan C ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b YALE CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug efflux; Novobiocin; Topoisomerase II; VP 16

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME INHIBITOR; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; NOVOBIOCIN;

ARTICLE; CELL CULTURE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; DNA TOPOISOMERASES, TYPE II; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NOVOBIOCIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034572287     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747585     Document Type: Article

References (16)

1. Gellert, M. DNA topoisomerases. Ann. Rev. Biochem. 50:879-910; 1981.
2. Drlica, K.; Franco, R. J. Inhibitors of DNA topoisomerases. Biochemistry 27:2253-2259; 1988.
3. Downes, C. S.; Ord, M. J.; Mulligan, A. M.; Collins, A. R. S.; Johnson, R. T. Novobiocin inhibition of DNA excision repair may occur through effects on mitochondrial structure and ATP metabolism, not on repair topoisomerases. Carcinogenesis 6:1343-1352; 1985.
4. + cells. Int. J. Cancer 52:903-909; 1992.
5. Rappa, G.; Lorico, A.; Sartorelli, A. C. Potentiation by novobiocin of the cylotoxic activity of etoposide (VP-16) and teniposide (VM-26). Int. J. Cancer 51:780-787; 1992.
6. Rappa, G.; Lorico, A.; Sartorelli, A. C. Reversal of etoposide resistance in non P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Cancer Res. 53:5487-5493; 1993.
7. Rappa, G.; Murren, J. R.; Lorico, A.; Sartorelli, A. C. Novobiocin-induced VP-16 accumulation and MRPI expression in human leukemias. Anticancer Drug Design 15:127-134; 2000.
8. Murren, J. R.; Lorico, A.; Di Stasio, S. A.; McKeon, A.; Egorin, M. J.; Sartorelli, A. C.; Rappa, G. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies. Cancer J. (in press).
9. Hinman, J. W.; Caron, E. L.; Hoeksema, H. The structure of novobiocin. J. Am. Chem. Soc. 79:3789-3800; 1957.
10. Zuhowski, E. G.; Gutheil, J. C.; Egorin, M. J. Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum. Chromatogr. B Biomed. Appl. 655:147-152; 1994.
11. Rappa, G.; Lorico, A.; Flavell, R. A.; Sartorelli, A. C. Evidence that the multidrug resistance protein (MRP) functions as a cotransporter of glutathione and natural product toxins. Cancer Res. 57:5232-5237; 1997.
12. Liu, L. F.; David, J. L.; Calendar, R. Novel topologically knotted DNA from bacteriophage P4 capsids: Studies with DNA topoisomerases. Nucleic Acids Res. 9:3979-3989; 1981.
13. + monomyelocytic leukemia cells by inhibitors of topoisomerase II. Cancer Res. 50:6723-6730; 1990.
14. Darnowski, J. W.; Holdridge, C.; Handschumacher, R. E. Concentrative uridine transport by murine splenocytes: Kinetics, substrate specificity, and sodium dependency. Cancer Res. 47:2614-2619; 1987.
15. Eder, J. P.; Teicher, B. A.; Holden, S. A.; Cathcart, K. N. S.; Schnipper, L. E. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J. Clin. Invest. 79:1524-1528; 1987.
16. Eder, J. P.; Wheeler, C. A.; Teicher, B. A.; Schnipper, L. E. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 51:510-513; 1991.